![]() | |
Clinical data | |
---|---|
Trade names | Cymerin |
Other names | 1-(2-chloroethyl)-1-nitroso-3-([(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)urea |
AHFS/ Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C10H18ClN3O7 |
Molar mass | 327.72 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Ranimustine ( INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia [1] and polycythemia vera. [2]
It has never been filed for FDA evaluation in the United States, where it is not marketed.
Ranimustine is made by reacting the primary amine of a pyranose sugar (2) with o-nitrophenyl N-(2-chloroethyl)-N-nitrosocarbamate (1) to form the nitrosourea group. [3] [4]
![]() | |
Clinical data | |
---|---|
Trade names | Cymerin |
Other names | 1-(2-chloroethyl)-1-nitroso-3-([(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)urea |
AHFS/ Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C10H18ClN3O7 |
Molar mass | 327.72 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Ranimustine ( INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia [1] and polycythemia vera. [2]
It has never been filed for FDA evaluation in the United States, where it is not marketed.
Ranimustine is made by reacting the primary amine of a pyranose sugar (2) with o-nitrophenyl N-(2-chloroethyl)-N-nitrosocarbamate (1) to form the nitrosourea group. [3] [4]